EUVIMEDEUVIMED entdecken
Crossref

Liquid biopsy‐based circulating tumour ( ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results

Douglas A Mata iD, Jessica K Lee, Vignesh Shanmugam, Chelsea B Marcus, Alexa B Schrock, Erik A Williams, Lauren L Ritterhouse, Richard A Hickman, Tyler Janovitz, Nimesh R Patel, Benjamin R Kroger, Jeffrey S Ross und 7 weitere

Histopathology · 2024

DOI: 10.1111/his.15168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2024. Verfasst von Douglas A Mata und 18 weiteren Autor:innen. Beteiligte Einrichtung: Foundation Medicine, Inc., Cambridge, MA, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, High-Throughput Nucleotide Sequencing, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Liquid biopsy (LBx)‐based next‐generation sequencing (NGS) of circulating tumour DNA (ctDNA) can facilitate molecular profiling of haematopoietic neoplasms (HNs), particularly when tissue‐based NGS is infeasible. Methods and Results We studied HN LBx samples tested with FoundationOne Liquid CDx, FoundationOne Liquid, or FoundationACT between July 2016 and March 2022. We identified 271 samples: 89 non‐Hodgkin lymphoma (NHL), 43 plasma‐cell neoplasm (PCN), 41 histiocytoses, 27 myelodysplastic syndrome (MDS), 25 diffuse large B‐cell lymphoma (DLBCL), 22 myeloproliferative neoplasm (MPN), 14 Hodgkin lymphoma (HL), and 10 acute myeloid leukaemia (AML). Among 73.4% with detectable pathogenic alterations, median maximum somatic allele frequency (MSAF) was 16.6%, with AML (36.2%), MDS (19.7%), and MPN (44.5%) having higher MSAFs than DLBCL (3.9%), NHL (8.4%), HL (1.5%), PCN (2.8%), and histiocytoses (1.8%) ( P = 0.001). LBx detected characteristic alterations across HNs, including in TP53 , KRAS , MYD88 , and BTK in NHLs; TP53 , KRAS , NRAS , and BRAF in PCNs; IGH in DLBCL; TP53 , ATM , and PDCD1LG2 in HL; BRAF and MAP2K1 in histiocytoses; TP53 , SF3B1 , DNMT3A , TET2 , and ASXL1 in MDS; JAK2 in MPNs; and FLT3 , IDH2 , and NPM1 in AML. Among 24 samples, the positive percent agreement by LBx was 75.7% for variants present in paired buffy coat, marrow, or tissues. Also, 75.0% of pairs exhibited alterations only present on LBx. These were predominantly subclonal (clonal fraction of 3.8%), reflecting the analytical sensitivity of LBx.

Conclusion

These data demonstrate that LBx can detect relevant genomic alterations across HNs, including at low clonal fractions, suggesting a potential clinical utility for identifying residual or emerging therapy‐resistant clones that may be undetectable in site‐specific tissue biopsies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAHigh-Throughput Nucleotide SequencingBiomarkers, TumorHumansLiquid BiopsyMaleMiddle AgedFemaleAgedAdultMutationHematologic NeoplasmsNucleophosminMyeloproliferative Disorders

Stichwörter der Autor:innen

haematopathologyliquid biopsynext‐generation sequencing

Substanzen

Circulating Tumor DNABiomarkers, TumorNucleophosmin

Autor:innen und Institutionen

  • Foundation Medicine, Inc., Cambridge, MA, USA.
  • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Foundation Medicine, Inc., Morrisville, NC, USA.
  • Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

ORCID-Profile: Douglas A Mata, Brennan Decker, Mina L Xu

Zitieren

APA

Mata, D. A., Lee, J. K., Shanmugam, V., Marcus, C. B., Schrock, A. B., Williams, E. A., Ritterhouse, L. L., Hickman, R. A., Janovitz, T., Patel, N. R., Kroger, B. R., Ross, J. S., Mirza, K. M., Oxnard, G. R., Vergilio, J. A., Elvin, J. A., Benhamida, J. K., Decker, B., & Xu, M. L. (2024). Liquid biopsy‐based circulating tumour ( ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology. https://doi.org/10.1111/his.15168

Vancouver

Mata DA, Lee JK, Shanmugam V, Marcus CB, Schrock AB, Williams EA, et al. Liquid biopsy‐based circulating tumour ( ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology. 2024. doi:10.1111/his.15168

BibTeX
@article{Mata2024,
  author = {Mata, Douglas A and Lee, Jessica K and Shanmugam, Vignesh and Marcus, Chelsea B and Schrock, Alexa B and Williams, Erik A and Ritterhouse, Lauren L and Hickman, Richard A and Janovitz, Tyler and Patel, Nimesh R and Kroger, Benjamin R and Ross, Jeffrey S and Mirza, Kamran M and Oxnard, Geoffrey R and Vergilio, Jo-Anne and Elvin, Julia A and Benhamida, Jamal K and Decker, Brennan and Xu, Mina L},
  title = {Liquid biopsy‐based circulating tumour ( ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results},
  journal = {Histopathology},
  year = {2024},
  doi = {10.1111/his.15168}
}
Kostenlos starten →